ACTU: Actuate Therapeutics Inc Market Cap to Revenue

Symbol and logo of brand Actuate Therapeutics Inc (ACTU)

Actuate Therapeutics, Inc. (ACTU) bases its efficiency on strict control of biosample transportation to ensure data accuracy. The development of therapies for melanoma, leukemia, and pancreatic cancer reduces approval risks, which is confirmed by the current price-to-sales ratio; the value of reflects this status. The company's prospects are further enhanced by the implementation of automated manipulators in laboratories to accelerate early-phase research validation.

ACTU - Actuate Therapeutics, Inc. Market Cap to Revenue over the range 07/04/2022 - 11/16/2026

Actuate Therapeutics, Inc (ACTU) - metric breakdowns and financial figures

- stock value and consensus price forecast:
General company analysis:ACTU - Actuate Therapeutics, Inc
Signature product of Actuate Therapeutics Inc.

The P/S ratio determines the investment attractiveness of Actuate Therapeutics, Inc. (ACTU) by comparing market capitalization with annual sales volume to identify whether the asset is overvalued relative to actual cash flows. By analyzing the P/S chart, an investor can gauge the level of venture risk within the non-cyclical nature of cancer treatment biotechnology, where demand is driven by medical necessity, ensuring high operational resilience of the business against macroeconomic shocks.

Who Actuate Therapeutics, Inc. competes with

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|Citius Oncology (CTOR) - Price-to-Revenue Ratio|HURA - Price-to-Revenue Coefficient|TARA (Protara Therapeutics, Inc.) - P/S Multiple|P/S Multiple Fate Therapeutics Inc|P/S Multiple WHWK|P/S Multiple TScan Therapeutics Inc (TCRX)|Price-to-Revenue Ratio championsoncology.com CSBR|XBIT - Market Cap to Revenue|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (OS Therapies)|RADX: P/S Multiple|Artiva Biotherapeutics Inc. - Market Capitalization-to-Revenue Ratio|ANL (Adlai Nortye) - P/S Multiple|P/S Multiple verupharma.com|Market Cap to Revenue TPST (tempesttx.com)|Market Cap to Revenue Xilio Therapeutics Inc XLO|P/S Multiple RENB (Enochian BioSciences)|Mural Bio - Price-to-Revenue Ratio|KAPA - Price-to-Revenue Ratio|OnKure Therapeutics (OKUR) - Market Cap to Revenue|GDTC: P/S Multiple|Price to Sales Curis Corp (CRIS)|APLM (apollomicsinc.com) - P/S Multiple|Market Cap to Revenue Tharimmune Corp (THAR)|P/S Multiple ADVB|GNPX - Price to Sales|Price-to-Revenue Ratio calidibio.com CLDI|SBFM - Market Cap to Revenue|XBIO - Price-to-Revenue Ratio|SLRX: Price-to-Revenue Ratio|Purple Biotech (PPBT) - Price-to-Revenue Ratio|AON - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd